Skip to main content

Table 1 Characteristics of the study cohort

From: Comparison of the prognosis for different onset stage of cardiogenic shock secondary to ST-segment elevation myocardial infarction

 

Non-CS (n = 562)

CS on admission (n = 32)

Developed CS (n = 81)

p-value

Age (years), mean ± SD

64 ± 12.7

66 ± 11.7

64 ± 12.7

0.593

Male sex, n (%)

444 (79)

25 (78)

64 (79)

0.993

Hypertension, n (%)

359 (64)

16 (50)

44 (54)

0.089

Diabetes, n (%)

142 (25)

14 (44)

13 (16)

0.009#, &&

Smoking, n (%)

315 (56)

17 (53)

46 (57)

0.938

Prior stroke, n (%)

76 (14)

7 (22)

10 (12)

0.383

Hyperlipidaemia, n (%)

44 (8)

5 (16)

5 (6)

0.233

Multivessel lesions, n (%)

140 (25)

13 (41)

32 (40)

0.005#, **

Known kidney dysfunction, n (%)

67 (12)

8 (25)

12 (15)

0.086

Prior MI, n (%)

15 (3)

3 (9)

2 (2)

0.09

Pre-procedural SBP (mmHg), mean ± SD

125 ± 18.9

80 ± 6.6

112 ± 20.6

< 0.001###, ***, &&&

Pre-procedural HR (bpm), mean ± SD

79 ± 14.7

114 ± 18.5

87 ± 16.5

< 0.001###, ***, &&&

Shock index, mean ± SD

0.65 ± 0.16

0.96 ± 0.22

0.81 ± 0.25

< 0.001###, ***, &&&

LVEF(%), mean ± SD

45 ± 5.6

44.6.4

45 ± 6.6

0.319

Creatinine (mmol/L), mean ± SD

70(24)

76 (39)

71 (24)

0.409

TG (mmol/L), mean ± SD

1.66 ± 1.09

1.39 + ±0.73

1.61 ± 0.88

0.377

TCh (mmol/L), mean ± SD

4.29 ± 1.02

4.27 ± 1.19

4.27 ± 0.97

0.985

LDL-C (mmol/L), mean ± SD

2.38 ± 0.74

2.46 ± 0.84

2.41 ± 0.70

0.792

HDL-C (mmol/L), mean ± SD

1.00 ± 0.38

1.00 ± 0.28

0.95 ± 0.34

0.525

Symptom-wire interval (min),median (IQR)

240 (328)

168(202)

237 (242)

0.067

IABP utility, n (%)

15 (3)

8 (25)

21 (26)

< 0.001###, ***

Anterior MI, n (%)

275 (49)

10 (31)

29 (36)

0.018#,*

Killips classification

< 0.001###,*,&&&

 I, n (%)

463 (82)

0

62 (77)

 

 II, n (%)

88 (16)

0

13 (16)

 

 III, n (%)

12 (2)

0

6 (7)

 

 V, n (%)

0

32 (100)

0

 

Post-procedure TIMI flow

0.079

 3, n (%)

557 (99)

31 (97)

78 (96)

 2, n (%)

4 (1)

0 (0)

3 (4)

 1, n (%)

1 (0)

1 (3)

0 (0)

IRA

< 0.001##, *

 LM/LM-LAD, n (%)

286 (51)

10 (31)

29 (36)

 LCX/OM, n (%)

90 (16)

2 (6)

11 (13)

 RCA/PDA/PL, n (%)

186 (33)

20 (63)

41 (51)

Medicine

 β blocker, n (%)

483 (86)

21 (67)

63 (78)

0.177

 ACEI/ARB, n (%)

427 (76)

21 (67)

54 (67)

0.517

 Aldactone, n (%)

90 (16)

11 (33)

15 (18)

0.427

  1. SBP Stytolic blood pressure, HR Heart rate, bpm beats per minute, SI Shock index, LVEF Left ventricular ejection fraction, TG Triglyceride, LDL-C Low density lipoprotein cholesterol, HDL-C High density lipoprotein cholesterol, TCh Total cholesterol, IABP Intra-aortic balloon pump;MI: myocardial infarction, TIMI Thrombolysis in myocardial infarction, IRA Infarct-related artery, LM Left main artery, LAD Left anterior descending branch, LCX Left circumflex branch, OM Obtuse marginal branch, RCA Right coronary artery, PDA Posterior descending artery, PL Posterior branch of left ventricle, ACEI Angitensin conveting enzyme inhibitor, ARB Angiotensin receptor blocker
  2. # P < 0.05, ##P < 0.01, ### P < 0.001: Non-CS group vs CS on admission group
  3. * P < 0.05,**P < 0.01,*** P < 0.001: Non-CS group vs Developed CS group
  4. & P < 0.05,&&P < 0.01, &&& P < 0.001: CS on admission group vs Developed CS group
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us